{"id":576325,"date":"2021-12-21T00:00:00","date_gmt":"2021-12-21T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/exincg0006-2021-biopharma-progressive-supranuclear-palsy-executive-insights-us-eu5-china-2021\/"},"modified":"2026-03-31T10:41:36","modified_gmt":"2026-03-31T10:41:36","slug":"exincg0006-2021-biopharma-progressive-supranuclear-palsy-executive-insights-us-eu5-china-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/exincg0006-2021-biopharma-progressive-supranuclear-palsy-executive-insights-us-eu5-china-2021\/","title":{"rendered":"Progressive Supranuclear Palsy\u00a0| Executive Insights | US\/EU5\/China | 2021"},"content":{"rendered":"<p>Executive Insights report on current medical practice, unmet need, and emerging treatments for spinocerebellar ataxia in the United States, Europe, and China.<\/p>\n","protected":false},"template":"","class_list":["post-576325","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-geography-china","biopharma-geography-us","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/576325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/576325\/revisions"}],"predecessor-version":[{"id":577556,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/576325\/revisions\/577556"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=576325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}